Brokerages Set Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Target Price at $9.50

by · The Markets Daily

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) has received an average rating of “Moderate Buy” from the nine research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $9.50.

Several research analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Xeris Biopharma in a research note on Friday, January 9th. Piper Sandler upped their price objective on shares of Xeris Biopharma from $6.00 to $8.00 and gave the stock a “neutral” rating in a report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xeris Biopharma in a research report on Wednesday, October 8th. Barclays began coverage on shares of Xeris Biopharma in a report on Monday, December 8th. They issued an “overweight” rating and a $9.00 target price for the company. Finally, Zacks Research cut Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 30th.

View Our Latest Stock Report on XERS

Insider Activity

In related news, insider Beth Hecht sold 16,667 shares of the stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $7.40, for a total transaction of $123,335.80. Following the transaction, the insider owned 1,336,843 shares of the company’s stock, valued at approximately $9,892,638.20. This represents a 1.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John Johnson sold 135,400 shares of the business’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $7.22, for a total transaction of $977,588.00. Following the sale, the director owned 698,083 shares in the company, valued at $5,040,159.26. This trade represents a 16.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 263,550 shares of company stock worth $1,917,672 in the last quarter. Insiders own 6.47% of the company’s stock.

Institutional Investors Weigh In On Xeris Biopharma

A number of hedge funds have recently added to or reduced their stakes in XERS. Royal Bank of Canada boosted its position in Xeris Biopharma by 1,411.2% in the 1st quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock valued at $1,170,000 after buying an additional 198,984 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Xeris Biopharma by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock valued at $461,000 after purchasing an additional 3,594 shares during the period. Millennium Management LLC grew its stake in Xeris Biopharma by 19.0% during the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock worth $12,726,000 after purchasing an additional 369,420 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after purchasing an additional 1,199,435 shares during the period. Finally, Caxton Associates LLP acquired a new stake in Xeris Biopharma in the 1st quarter valued at about $170,000. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Xeris Biopharma Stock Up 1.5%

XERS stock opened at $7.52 on Wednesday. The business has a fifty day moving average of $7.23 and a two-hundred day moving average of $7.27. The stock has a market cap of $1.25 billion, a price-to-earnings ratio of -75.19 and a beta of 0.50. Xeris Biopharma has a 52-week low of $3.15 and a 52-week high of $10.08.

Xeris Biopharma (NASDAQ:XERS – Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.00 EPS for the quarter, missing the consensus estimate of $0.01 by ($0.01). The firm had revenue of $74.38 million during the quarter, compared to analyst estimates of $74.19 million. As a group, sell-side analysts anticipate that Xeris Biopharma will post -0.41 EPS for the current year.

About Xeris Biopharma

(Get Free Report)

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.

See Also